Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure

被引:29
作者
Freestone, Bethan [1 ]
Gustasson, Finn
Chong, Aun Yeong [1 ]
Corell, Pernille [2 ]
Kistorp, Caroline [3 ]
Hildebrandt, Per [4 ]
Lip, Gregory Y. H. [1 ]
机构
[1] City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7HQ, W Midlands, England
[2] Frederiksberg Univ Hosp, Dept Cariol & Endocrinol E, Frederiksberg, Denmark
[3] Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark
[4] Roskilde Univ Hosp, Dept Med, Roskilde, Denmark
关键词
atrial fibrillation; heart failure; N-terminal pro B-type natriuretic peptide; von Willebrand factor;
D O I
10.1378/chest.07-2557
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Endothelial dysfunction is present in patients with heart failure (HF) due to left ventricular systolic dysfunction, as well as in patients with atrial fibrillation (AF) who have normal cardiac function. it is unknown whether AF influences the degree of endothelial dysfunction in patients with systolic HF. Methods: We measured levels of plasma von Willebrand factor (vWF) and E-selectin (as indexes of endothelial damage/dysfunction and endothelial activation, respectively; both enzyme-linked immunosorbent assay) in patients with AF and HF (AF-HF), who were compared to patients with sinus rhythm and HF (SR-HF), as well as in age-matched, healthy, control subjects. We also assessed the relationship of vWF and E-selectin to plasma N-terminal pro B-type natriuretic peptide (NTpro-BNP), a marker for HF severity and prognosis. Results: One hundred ninety patients (73% men; mean age, 69.0 +/- 10.1 years [+/- SD]) with systolic HF were studied, who were compared to 117 healthy control subjects: 52 subjects (27%) were in AF, while 138 subjects (73%) were in sinus rhythm. AF-HF patients were older than SR-HF patients (p = 0.046), but left ventricular ejection fraction and New York Heart Association class were similar. There were significant differences in NT-proBNP (p < 0.0001) and plasma vWF (p = 0.003) between patients and control subjects. On Tukey post hoe analysis, AF-HF patients had significantly increased NT-proBNP (p < 0.001) and vWF (p = 0.0183) but not E-selectin (p = 0.071) levels when compared to SR-HF patients. On multivariate analysis, the presence of AF was related to plasma vWF levels (p = 0.018). Plasma vWF was also significantly correlated with NT-proBNP levels (Spearman r = 0.139; p = 0.0117). Conclusions: There is evidence of greater endothelial damage/dysfunction in AF-HF patients when compared to SR-HF patients. The clinical significance of this is unclear but may have prognostic value.
引用
收藏
页码:1203 / 1208
页数:6
相关论文
共 50 条
  • [21] Distinguishable optimal levels of plasma B-type natriuretic peptide in heart failure management based on complicated atrial fibrillation
    Koitabashi, T
    Inomata, T
    Niwano, S
    Nishii, M
    Takeuchi, I
    Nakano, H
    Shinagawa, H
    Takehana, H
    Izumi, T
    INTERNATIONAL HEART JOURNAL, 2005, 46 (03) : 453 - 464
  • [22] Decrease in B-Type Natriuretic Peptide Levels and Successful Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure
    Yanagisawa, Satoshi
    Inden, Yasuya
    Kato, Hiroyuki
    Fujii, Aya
    Mizutani, Yoshiaki
    Ito, Tadahiro
    Kamikubo, Yosuke
    Kanzaki, Yasunori
    Hirai, Makoto
    Murohara, Toyoaki
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2016, 39 (03): : 225 - 234
  • [23] Correlation between B-Type Natriuretic Peptide and N-Terminal pro-B-Type Natriuretic Peptide in a Large Japanese Population at Risk of Stage A Heart Failure
    Taki, Mizuri
    Hoshide, Satoshi
    Kono, Ken
    Kario, Kazuomi
    PULSE, 2018, 6 (1-2) : 1 - 8
  • [24] Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients
    Imamura, Teruhiko
    Kinugawa, Koichiro
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (09) : 2856 - 2861
  • [25] Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation
    Krishnamoorthy, Suresh
    Khoo, Chee Wah
    Lim, Hoong S.
    Lane, Deirdre A.
    Pignatelli, Pasquale
    Basili, Stefania
    Violi, Francesco
    Lip, Gregory Y. H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2013, 43 (10) : 1032 - 1038
  • [26] Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort
    Li, Linzi
    Selvin, Elizabeth
    Lutsey, Pamela L.
    Hoogeveen, Ron C.
    O'Neal, Wesley T.
    Soliman, Elsayed Z.
    Chen, Lin Y.
    Alonso, Alvaro
    AMERICAN HEART JOURNAL, 2018, 204 : 119 - 127
  • [27] Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design
    Engdahl, Johan
    Svennberg, Emma
    Friberg, Leif
    Al-Khalili, Faris
    Frykman, Viveka
    Gudmundsdottir, Katrin Kemp
    Fredriksson, Tove
    Rosenqvist, Marten
    EUROPACE, 2017, 19 (02): : 297 - 302
  • [28] The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation
    Shelton, Rhidian J.
    Clark, Andrew L.
    Goode, Kevin
    Rigby, Alan S.
    Cleland, John G. F.
    EUROPEAN HEART JOURNAL, 2006, 27 (19) : 2353 - 2361
  • [29] Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction
    Cui, Kun
    Huang, Wei
    Fan, Jinqi
    Lei, Han
    MEDICINE, 2018, 97 (36)
  • [30] Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide
    Yasuyuki Shiraishi
    Toshiyuki Nagai
    Shun Kohsaka
    Ayumi Goda
    Yuji Nagatomo
    Atsushi Mizuno
    Takashi Kohno
    Alan Rigby
    Keiichi Fukuda
    Tsutomu Yoshikawa
    Andrew L. Clark
    John G. F. Cleland
    Clinical Research in Cardiology, 2018, 107 : 1103 - 1110